GeneWEAVE Receives Two Prestigious Awards from the DxMA

Share Article

Molecular Diagnostics Company Wins First-Place at 2015 DxMA Global Marketing Summit

News Image

GeneWEAVE , Inc., a clinical diagnostics company addressing multi-drug-resistant organisms (MDRO), today announced that it received two first place DxMA Creative Communication Awards for its technology explainer video and tradeshow campaign. The goals of both programs were to introduce and describe the Company’s Smarticles™ technology, a new class of molecular diagnostics that can quickly detect MDROs and assess antibiotic susceptibility directly from clinical samples. Presented at the Dx Creative Communications Awards program in conjunction with the annual DxMA Global Marketing Summit, the awards honor the best of the best in diagnostics advertising, marketing and promotional programming.

“After spending several years quietly developing this novel and powerful new class of molecular diagnostics, we are thrilled that our initial campaigns to introduce the transformative and game-changing power of our Smarticles™ have resulted in being honored by our peers and the DxMA,” said Steve Tablak, CEO at GeneWEAVE. “The positive attention we have received since unveiling the company at the Association for Molecular Pathology meeting last November is a true testament to the unmet need for fast, powerful and effective solutions that deliver real-time, reliable susceptibility results for dangerous multidrug-resistant pathogens like MRSA and CRE.”

“The marketing team at GeneWEAVE has done a wonderful job of introducing their exciting new technology to address a rising global concern related to MDROs,” noted Bob McGonnagle, Publisher of CAP Today. “The DxMA awards are the longest running advertising media competition in the healthcare field and the judging is done by objective experts who work inside and outside the world of diagnostics. We think these awards speak to the exciting promise of GeneWEAVE.”

About GeneWEAVE
GeneWEAVE, Inc., based in Los Gatos, Calif., is a privately-held in vitro diagnostics company that is advancing clinical microbiology with diagnostic solutions to aid healthcare providers in the fight against drug-resistant bacteria by enabling impactful surveillance programs, early therapy guidance and successful antibiotic stewardship. The company’s innovative and proprietary Smarticles™ technology harnesses the power of biology to rapidly detect drug resistance and measure susceptibility information without the need for enrichment, culture, or sample preparation. We call this new paradigm, “Sample-In/Susceptibility-Out”.

About DxMA (Diagnostics Marketing Association)
The DxMA builds diagnostic industry leadership by providing knowledge and opportunities for professional development and the exchange of ideas. We serve marketing, regulatory compliance, business development and medical affairs professionals who have devoted their careers to the diagnostics, device and life science market segments. Members benefit from continued education and insight, networking with marketers from leading diagnostic companies and service providers, and programs, such as the DxMA Seminar @ AACC and DxMA Global Marketing Summit. For more information on the DxMA, visit http://www.dxma.org.

GeneWEAVE and Smarticles are trademarks of GeneWEAVE, Inc. All rights reserved.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jean Nelson
Visit website